{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:47:08Z","timestamp":1792900028391,"version":"4.5.0"},"reference-count":40,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Growing evidence has linked bullous pemphigoid (BP) to immune checkpoint inhibitor (ICI) therapy in cancer treatment. However, the immunological features of ICI-associated BP (ICI-BP) are not yet fully elucidated. In order to characterize the humoral response in ICI BP patients and investigate whether their epitope profile differs from idiopathic BP (IBP), 53 ICI-BP patients were enrolled, immunologically characterized and compared with 59 IBP patients. ICI-BP had a distinctive IgG humoral profile, with reduced reactivity toward BP230 and recognition of multiple BP180 epitopes beyond the immunodominant extracellular noncollagenous 16A domain (NC16A). Specifically, reactivity to BP180 ectodomain was present in 94% of ICI-BP and 78% of IBP (p=0.044). Moreover, BP180 C-terminal epitope was more frequently targeted in ICI-BP than IBP (72% vs 41%, p=0.002). Notably, the combined use of an in-house BP180 ectodomain ELISA and the commercial BP180 test increased diagnostic sensitivity from 83% to 100%. Enhanced IgG reactivity toward nonimmunodominant epitopes, and especially C-terminal epitope recognition, characterize the humoral immune response in ICI-BP. Our data suggest that combining NC16A and fulllength BP180 ectodomain ELISAs may help reduce diagnostic delay in ICI-BP patients, in whom a timely diagnosis is crucial to appropriately manage the disease and ultimately avoid discontinuation ofcancer therapy.<\/jats:p>","DOI":"10.2340\/actadv.v106.adv-2026-0336","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T04:29:02Z","timestamp":1782793742000},"source":"Crossref","is-referenced-by-count":1,"title":["Distinctive Reactivity to the C-terminal Epitope of BP180 Characterizes Immune Checkpoint Inhibitor\u2013associated Bullous Pemphigoid, and an ELISA Based on the BP180 Ectodomain Enables Prompt Diagnosis in a Subset of Patients"],"prefix":"10.2340","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7172-619X","authenticated-orcid":false,"given":"Anna","family":"Pira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7224-6507","authenticated-orcid":false,"given":"Martina","family":"Merli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7004-5031","authenticated-orcid":false,"given":"Feliciana","family":"Mariotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3451-3624","authenticated-orcid":false,"given":"Marco","family":"Andreani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8160-4169","authenticated-orcid":false,"given":"Angelo Valerio","family":"Marzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0898-0045","authenticated-orcid":false,"given":"Clara","family":"De Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9679-4711","authenticated-orcid":false,"given":"Rosa","family":"Falcone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Testa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7506-2383","authenticated-orcid":false,"given":"Battarra","family":"Mariarosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7015-8319","authenticated-orcid":false,"given":"Maurizio","family":"Romagnuolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1632-7791","authenticated-orcid":false,"given":"Pietro","family":"Sollena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9041-8141","authenticated-orcid":false,"given":"Federica","family":"De Galitiis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7787-4433","authenticated-orcid":false,"given":"Emiliano","family":"Antiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Maglie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6119-1870","authenticated-orcid":false,"given":"Dario","family":"Didona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4971-5985","authenticated-orcid":false,"given":"Jo Linda Maria","family":"Sinagra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7471-3471","authenticated-orcid":false,"given":"Marzia","family":"Caproni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5494-2461","authenticated-orcid":false,"given":"Michael","family":"Hertl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3108-4123","authenticated-orcid":false,"given":"Emanuele","family":"Cozzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Vezzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5238-2336","authenticated-orcid":false,"given":"Laura","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3032-2217","authenticated-orcid":false,"given":"Giovanni","family":"Paolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2599-807X","authenticated-orcid":false,"given":"Sofia","family":"Verkhovskaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4194-932X","authenticated-orcid":false,"given":"Luca","family":"Fania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1049-4676","authenticated-orcid":false,"given":"Giulia","family":"Gasparini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9147-4249","authenticated-orcid":false,"given":"Anna Rita","family":"Giampetruzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6635-0490","authenticated-orcid":false,"given":"Biagio","family":"Didona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4185-9586","authenticated-orcid":false,"given":"Pietro","family":"Quaglino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6106-599X","authenticated-orcid":false,"given":"Giovanni","family":"Di Zenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"160931","doi-asserted-by":"crossref","unstructured":"Di Zenzo G, Della Torre R, Zambruno G, Borradori L. Bullous pemphigoid: Ffrom the clinic to the bench. Clin Dermatol 2012; 30: 3\u201316.","DOI":"10.1016\/j.clindermatol.2011.03.005"},{"key":"160932","doi-asserted-by":"crossref","unstructured":"Genovese G, Di Zenzo G, Cozzani E, Berti E, Cugno M, Marzano AV. New insights into the pathogenesis of bullous pemphigoid: 2019 Update. Front Immunol 2019; 10: 1506.","DOI":"10.3389\/fimmu.2019.01506"},{"key":"160933","doi-asserted-by":"crossref","unstructured":"Swiderski M, Vinogradova Y, Knaggs RD, Harman K, Harwood RH, Prasad V, et al. Association between drugs and vaccines commonly prescribed to older people and bullous pemphigoid: a case-control study. Br J Dermatol 2025; 192: 440\u2013449.","DOI":"10.1093\/bjd\/ljae416"},{"key":"160934","doi-asserted-by":"crossref","unstructured":"Merli M, Accorinti M, Romagnuolo M, Marzano A, Di Zenzo G, Moro F, et al. Autoimmune bullous dermatoses in cancer patients treated by immunotherapy: a literature review and Italian multicentric experience. Front Med (Lausanne) 2023; 10: 1208418.","DOI":"10.3389\/fmed.2023.1208418"},{"key":"160935","doi-asserted-by":"crossref","unstructured":"Siegel J, Totonchy M, Damsky W, Berk-Krauss J, Castiglione F Jr, Sznol M, et al. Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. J Am Acad Dermatol 2018; 79: 1081\u20131088.","DOI":"10.1016\/j.jaad.2018.07.008"},{"key":"160936","doi-asserted-by":"crossref","unstructured":"Kawsar A, Edwards C, Patel P, Heywood RM, Gupta A, Mann J, et al. Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: Aa multicentre observational study. Br J Dermatol 2022; 187: 981\u2013987.","DOI":"10.1111\/bjd.21836"},{"key":"160937","doi-asserted-by":"crossref","unstructured":"Said JT, Liu M, Talia J, Singer SB, Semenov YR, Wei EX, et al. Risk factors for the development of bullous pemphigoid in US patients receiving immune checkpoint inhibitors. JAMA Dermatol 2022; 158: 552\u2013557.","DOI":"10.1001\/jamadermatol.2022.0354"},{"key":"160938","doi-asserted-by":"crossref","unstructured":"Andreani M, Mariotti F, Pira A, Locatelli F, Testa G, Battarra M, et al. HLA alleles associated to susceptibility to gliptin-associated bullous pemphigoid in Italian patients. HLA 2024; 104: e15616.","DOI":"10.1111\/tan.15616"},{"key":"160939","doi-asserted-by":"crossref","unstructured":"Gandarillas S, Berger A, Stephenson R, Mehregan D, Dasgeb B. Enriched class II HLA inherence in patients with checkpoint inhibitor-associated bullous pemphigoid. Int J Dermatol 2025; 64: 399\u2013401.","DOI":"10.1111\/ijd.17563"},{"key":"160940","doi-asserted-by":"crossref","unstructured":"Gandarillas S, Newland ES, Toppmeyer D, Stephenson R, Denzin L, Dasgeb B. HLA inherence as a potential parameter in checkpoint inhibitor-associated autoimmune adverse event assessment. Front Med 2024; 10: 1288844.","DOI":"10.3389\/fmed.2023.1288844"},{"key":"160941","doi-asserted-by":"crossref","unstructured":"Mariotti F, Pira A, De Luca N, Giampetruzzi AR, Russo F, Cerri A, et al. Bullous pemphigoid and mucous membrane pemphigoid humoral responses differ in reactivity towards BP180 midportion and BP230. Front Immunol 2024; 15: 1494294.","DOI":"10.3389\/fimmu.2024.1494294"},{"key":"160942","doi-asserted-by":"crossref","unstructured":"Salemme A, Fania L, Scarabello A, Caproni M, Marzano AV, Cozzani E, et al. Gliptin-associated bullous pemphigoid shows peculiar features of anti-BP180 and -BP230 humoral response: Results of a multicenter study. J Am Acad Dermatol 2022; 87: 56\u201363.","DOI":"10.1016\/j.jaad.2022.02.036"},{"key":"160943","doi-asserted-by":"crossref","unstructured":"Mariotti F, Grosso F, Terracina M, Ruffelli M, Cordiali-Fei P, Sera F, et al. Development of a novel ELISA system for detection of anti-BP180 IgG and characterization of autoantibody profile in bullous pemphigoid patients. Br J Dermatol 2004; 151: 1004\u20131010.","DOI":"10.1111\/j.1365-2133.2004.06245.x"},{"key":"160944","doi-asserted-by":"crossref","unstructured":"Thoma-Uszynski S, Uter W, Schwietzke S, Schuler G, Borradori L, Hertl M. Autoreactive T and B cells from bullous pemphigoid (BP) patients recognize epitopes clustered in distinct regions of BP180 and BP230. J Immunol 2006; 176: 2015\u20132023.","DOI":"10.4049\/jimmunol.176.3.2015"},{"key":"160945","doi-asserted-by":"crossref","unstructured":"Saffuri N, Boyango I, Cohen I, Ali-Saleh Z, Dawood M, Khamaysi Z, et al. The immunophenotype of immune checkpoint-induced bullous pemphigoid: Aa cohort study. Cancer Immunol Immunother 2025; 74: 360.","DOI":"10.1007\/s00262-025-04172-3"},{"key":"160946","doi-asserted-by":"crossref","unstructured":"Borradori L, Van Beek N, Feliciani C, Tedbirt B, Antiga E, Bergman R, et al. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol 2022; 36: 1689\u20131704.","DOI":"10.1111\/jdv.18220"},{"key":"160947","doi-asserted-by":"crossref","unstructured":"Di Zenzo G, Thoma-Uszynski S, Fontao L, Calabresi V, Hofmann SC, Hellmark T, et al. Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid. Clin Immunol 2008; 128: 415\u2013426.","DOI":"10.1016\/j.clim.2008.04.012"},{"key":"160948","doi-asserted-by":"crossref","unstructured":"Gammon WR, Briggaman RA, Inman AO III, Queen LL, Wheeler CE. Differentiating anti-lamina lucida and anti-sublamina densa anti-BMZ antibodies by indirect immunofluorescence on 1.0 M sodium chloride-separated skin. J Invest Dermatol 1984; 82: 139\u2013144.","DOI":"10.1111\/1523-1747.ep12259692"},{"key":"160949","doi-asserted-by":"crossref","unstructured":"Wang J, Hu X, Jiang W, Zhou W, Tang M, Wu C, et al. Analysis of the clinical characteristics of pembrolizumab-induced bullous pemphigoid. Front Oncol 2023; 13: 1095694.","DOI":"10.3389\/fonc.2023.1095694"},{"key":"160950","doi-asserted-by":"crossref","unstructured":"Lopez AT, Khanna T, Antonov N, Audrey-Bayan C, Geskin L. A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors. Int J Dermatol 2018; 57: 664\u2013669.","DOI":"10.1111\/ijd.13984"},{"key":"160951","doi-asserted-by":"crossref","unstructured":"Moro F, Fania L, Sinagra JLM, Salemme A, Di Zenzo G. Bullous pemphigoid: Trigger and predisposing factors. Biomolecules 2020; 10: 1432.","DOI":"10.3390\/biom10101432"},{"key":"160952","doi-asserted-by":"crossref","unstructured":"de Groot PM, Wu CC, Carter BW, Munden RF. The epidemiology of lung cancer. Transl Lung Cancer Res 2018; 7: 220\u2013233.","DOI":"10.21037\/tlcr.2018.05.06"},{"key":"160953","doi-asserted-by":"crossref","unstructured":"Olsen CM, Thompson JF, Pandeya N, Whiteman DC. Evaluation of sex-specific incidence of melanoma. JAMA Dermatol 2020; 156: 553\u2013560.","DOI":"10.1001\/jamadermatol.2020.0470"},{"key":"160954","doi-asserted-by":"crossref","unstructured":"Stelkovics E, Korom I, Marczinovits I, Molnar J, Rasky K, Raso E, et al. Collagen XVII\/BP180 protein expression in squamous cell carcinoma of the skin detected with novel monoclonal antibodies in archived tissues using tissue microarrays and digital microscopy. Appl Immunohistochem Mol Morphol 2008; 16: 433\u2013441.","DOI":"10.1097\/PAI.0b013e318162f8aa"},{"key":"160955","doi-asserted-by":"crossref","unstructured":"Krenacs T, Kiszner G, Stelkovics E, Balla P, Teleki I, Nemeth I, et al. Collagen XVII is expressed in malignant but not in benign melanocytic tumors and it can mediate antibody induced melanoma apoptosis. Histochem Cell Biol 2012; 138: 653\u2013667.","DOI":"10.1007\/s00418-012-0981-9"},{"key":"160956","doi-asserted-by":"crossref","unstructured":"Russo F, Pira A, Mariotti F, Papaccio F, Giampetruzzi AR, Bellei B, et al. The possible and intriguing relationship between bullous pemphigoid and melanoma: Sspeculations on significance and clinical relevance. Front Immunol 2024; 15: 1416473.","DOI":"10.3389\/fimmu.2024.1416473"},{"key":"160957","doi-asserted-by":"crossref","unstructured":"Koga H, Tsutsumi M, Teye K, Shirahama T, Ishii N, Azuma K, et al. Epitope spreading in immune checkpoint inhibitor-associated bullous pemphigoid. JAMA Dermatol 2025; 161: 557\u2013559.","DOI":"10.1001\/jamadermatol.2024.6665"},{"key":"160958","doi-asserted-by":"crossref","unstructured":"Di Zenzo G, Thoma-Uszynski S, Calabresi V, Fontao L, Hofmann SC, Lacour JP, et al. Demonstration of epitope-spreading phenomena in bullous pemphigoid: Rresults of a prospective multicenter study. J Invest Dermatol 2011; 131: 2271\u20132280.","DOI":"10.1038\/jid.2011.180"},{"key":"160959","doi-asserted-by":"crossref","unstructured":"Jensen-Jarolim E, Achatz G, Turner MC, Karagiannis S, Legrand F, Capron M, et al. AllergoOncology: the role of IgE-mediated allergy in cancer. Allergy 2008; 63: 1255\u20131266.","DOI":"10.1111\/j.1398-9995.2008.01768.x"},{"key":"160960","doi-asserted-by":"crossref","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. JCO 2018; 36: 1714\u20131768.","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"160961","doi-asserted-by":"crossref","unstructured":"Barrios DM, Phillips GS, Geisler AN, Trelles SR, Markova A, Noor SJ, et al. IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies. Ann Oncol 2021; 32: 736\u2013745.","DOI":"10.1016\/j.annonc.2021.02.016"},{"key":"160962","doi-asserted-by":"crossref","unstructured":"Avallone G, Maronese CA, Zussino M, Muratori S, Ferrucci SM, Quaglino P, et al. Effectiveness of dupilumab and omalizumab in bullous pemphigoid: A nationwide retrospective cohort study. J Dermatol 2025; 52: 983\u20131000.","DOI":"10.1111\/1346-8138.17742"},{"key":"160963","doi-asserted-by":"crossref","unstructured":"Chen J, Xu D, He Z, Ma S, Liu J, Dai X, et al. Successful treatment of immune checkpoint inhibitor-induced bullous pemphigoid with omalizumab: A case report and review of the literature. Clin Cosmet Investig Dermatol 2024; 17: 2865\u20132874.","DOI":"10.2147\/CCID.S487711"},{"key":"160964","doi-asserted-by":"crossref","unstructured":"Dousset L, Pacaud A, Barnetche T, Kostine M, Dutriaux C, Pham-Ledard A, et al. Analysis of tumor response and clinical factors associated with vitiligo in patients receiving anti-programmed cell death-1 therapies for melanoma: A cross-sectional study. JAAD Int 2021; 5: 112\u2013120.","DOI":"10.1016\/j.jdin.2021.09.002"},{"key":"160965","doi-asserted-by":"crossref","unstructured":"Nelson CA, Singer S, Chen T, Puleo AE, Lian CG, Wei EX, et al. Bullous pemphigoid after anti-programmed death-1 therapy: A retrospective case-control study evaluating impact on tumor response and survival outcomes. J Am Acad Dermatol 2022; 87: 1400\u20131402.","DOI":"10.1016\/j.jaad.2019.12.068"},{"key":"160966","doi-asserted-by":"crossref","unstructured":"Asdourian MS, Shah N, Jacoby TV, Reynolds KL, Chen ST. Association of bullous pemphigoid with immune checkpoint inhibitor therapy in patients with cancer: A systematic review. JAMA Dermatol 2022; 158: 933\u2013941.","DOI":"10.1001\/jamadermatol.2022.1624"},{"key":"160967","doi-asserted-by":"crossref","unstructured":"Du Y, Wu W, Chen M, Dong Z, Wang F. Cutaneous adverse events and cancer survival prognosis with immune checkpoint inhibitor treatment: A systematic review and meta-analysis. JAMA Dermatol 2023; 159: 1093\u20131101.","DOI":"10.1001\/jamadermatol.2023.3003"},{"key":"160968","doi-asserted-by":"crossref","unstructured":"Grimaux X, Delva R, Jadaud E, Croue A. Nivolumab-induced bullous pemphigoid after radiotherapy and abscopal effect. Australas J Dermatol 2019; 60: e235\u2013e236.","DOI":"10.1111\/ajd.12987"},{"key":"160969","doi-asserted-by":"crossref","unstructured":"Zhang X, Sui D, Wang D, Zhang L, Wang R. Case rReport: A rare case of pembrolizumab-induced bullous pemphiRare Case of Pembrolizumab-Induced Bullous Pemphigoid. Front Immunol 2021; 12: 731774.","DOI":"10.3389\/fimmu.2021.731774"},{"key":"160970","doi-asserted-by":"crossref","unstructured":"Sowerby L, Dewan AK, Granter S, Gandhi L, LeBoeuf NR. Rituximab treatment of nivolumab-induced bullous pemphigoid. JAMA Dermatol 2017; 153: 603\u2013605.","DOI":"10.1001\/jamadermatol.2017.0091"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/46412\/54579","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/46412\/54580","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/46412\/54583","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/46412\/54579","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T04:30:14Z","timestamp":1782793814000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/46412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":40,"URL":"https:\/\/doi.org\/10.2340\/actadv.v106.adv-2026-0336","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,29]]}}}